Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) saw an uptick in trading volume on Wednesday . 3,240,671 shares changed hands during mid-day trading, an increase of 279% from the previous session’s volume of 854,307 shares.The stock last traded at $0.70 and had previously closed at $0.61.

Several research firms recently weighed in on SNSS. ValuEngine upgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, May 24th. Zacks Investment Research cut shares of Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 4th. HC Wainwright reiterated a “hold” rating and issued a $0.50 target price on shares of Sunesis Pharmaceuticals in a research note on Tuesday, March 12th. Finally, Oppenheimer set a $6.00 target price on shares of Sunesis Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, March 8th.

The company has a market cap of $50.89 million, a price-to-earnings ratio of -0.94 and a beta of 2.98.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. On average, analysts anticipate that Sunesis Pharmaceuticals, Inc. will post -0.44 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Algert Global LLC bought a new position in Sunesis Pharmaceuticals during the first quarter worth about $25,000. Renaissance Technologies LLC bought a new position in Sunesis Pharmaceuticals during the first quarter worth about $75,000. Northern Trust Corp lifted its stake in Sunesis Pharmaceuticals by 51.3% during the first quarter. Northern Trust Corp now owns 107,116 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 36,296 shares during the period. BlackRock Inc. lifted its stake in Sunesis Pharmaceuticals by 27.2% during the first quarter. BlackRock Inc. now owns 219,135 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 46,852 shares during the period. Finally, Fosun International Ltd bought a new position in Sunesis Pharmaceuticals during the first quarter worth about $863,000. Institutional investors and hedge funds own 43.10% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Sunesis Pharmaceuticals (NASDAQ:SNSS) Sees Unusually-High Trading Volume” was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/sunesis-pharmaceuticals-nasdaqsnss-sees-unusually-high-trading-volume/3039663.html.

Sunesis Pharmaceuticals Company Profile (NASDAQ:SNSS)

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

See Also: Stop Order Uses For Individual Investors

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.